Annual EBITDA:
-$261.52M-$102.47M(-64.43%)Summary
- As of today, PHAT annual EBITDA is -$261.52 million, with the most recent change of -$102.47 million (-64.43%) on December 31, 2024.
- During the last 3 years, PHAT annual EBITDA has fallen by -$124.95 million (-91.49%).
- PHAT annual EBITDA is now -20411.53% below its all-time high of -$1.27 million, reached on December 31, 2018.
Performance
PHAT EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
-$15.12M+$44.64M(+74.70%)Summary
- As of today, PHAT quarterly EBITDA is -$15.12 million, with the most recent change of +$44.64 million (+74.70%) on September 30, 2025.
- Over the past year, PHAT quarterly EBITDA has increased by +$55.49 million (+78.59%).
- PHAT quarterly EBITDA is now -5539.93% below its all-time high of -$268.00 thousand, reached on September 30, 2018.
Performance
PHAT Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$212.78M+$55.49M(+20.68%)Summary
- As of today, PHAT TTM EBITDA is -$212.78 million, with the most recent change of +$55.49 million (+20.68%) on September 30, 2025.
- Over the past year, PHAT TTM EBITDA has increased by +$74.36 million (+25.90%).
- PHAT TTM EBITDA is now -79294.40% below its all-time high of -$268.00 thousand, reached on September 30, 2018.
Performance
PHAT TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
PHAT EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -64.4% | +78.6% | +25.9% |
| 3Y3 Years | -91.5% | +64.3% | -34.5% |
| 5Y5 Years | -4.2% | +53.8% | -139.9% |
PHAT EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -91.5% | at low | at high | +80.8% | -48.3% | +25.9% |
| 5Y | 5-Year | -110.6% | at low | at high | +80.8% | -139.9% | +25.9% |
| All-Time | All-Time | >-9999.0% | at low | -5539.9% | +80.8% | >-9999.0% | +25.9% |
PHAT EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | -$15.12M(+74.7%) | -$212.78M(+20.7%) |
| Jun 2025 | - | -$59.75M(+24.1%) | -$268.27M(+6.1%) |
| Mar 2025 | - | -$78.69M(-32.9%) | -$285.62M(-3.2%) |
| Dec 2024 | -$261.52M(-64.4%) | -$59.22M(+16.1%) | -$276.67M(+3.6%) |
| Sep 2024 | - | -$70.61M(+8.4%) | -$287.14M(-13.9%) |
| Jun 2024 | - | -$77.10M(-10.6%) | -$252.07M(-22.0%) |
| Mar 2024 | - | -$69.74M(-0.1%) | -$206.54M(-23.9%) |
| Dec 2023 | -$159.05M(+6.3%) | -$69.69M(-96.1%) | -$166.74M(-16.2%) |
| Sep 2023 | - | -$35.54M(-12.5%) | -$143.52M(+4.5%) |
| Jun 2023 | - | -$31.58M(-5.5%) | -$150.34M(+8.3%) |
| Mar 2023 | - | -$29.93M(+35.6%) | -$163.97M(+4.6%) |
| Dec 2022 | -$169.80M | -$46.47M(-9.7%) | -$171.82M(-8.6%) |
| Sep 2022 | - | -$42.35M(+6.3%) | -$158.25M(-6.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$45.21M(-19.7%) | -$148.90M(-7.2%) |
| Mar 2022 | - | -$37.78M(-14.8%) | -$138.88M(-3.2%) |
| Dec 2021 | -$136.57M(-10.0%) | -$32.91M(+0.3%) | -$134.56M(+12.6%) |
| Sep 2021 | - | -$33.01M(+6.2%) | -$154.01M(-0.2%) |
| Jun 2021 | - | -$35.19M(-5.2%) | -$153.75M(-11.0%) |
| Mar 2021 | - | -$33.46M(+36.1%) | -$138.50M(-10.5%) |
| Dec 2020 | -$124.16M(+50.5%) | -$52.36M(-59.9%) | -$125.36M(-41.3%) |
| Sep 2020 | - | -$32.74M(-64.2%) | -$88.70M(-42.5%) |
| Jun 2020 | - | -$19.94M(+1.9%) | -$62.24M(-47.2%) |
| Mar 2020 | - | -$20.32M(-29.6%) | -$42.29M(-92.5%) |
| Dec 2019 | -$250.95M(>-9900.0%) | -$15.69M(-149.7%) | -$21.97M(-249.7%) |
| Sep 2019 | - | -$6.28M(-2244.0%) | -$6.28M(-2244.0%) |
| Dec 2018 | -$1.27M | - | - |
| Sep 2018 | - | -$268.00K | -$268.00K |
FAQ
- What is Phathom Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is Phathom Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?
- What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is Phathom Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of PHAT is -$261.52M
What is the all-time high annual EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high annual EBITDA is -$1.27M
What is Phathom Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, PHAT annual EBITDA has changed by -$102.47M (-64.43%)
What is Phathom Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of PHAT is -$15.12M
What is the all-time high quarterly EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high quarterly EBITDA is -$268.00K
What is Phathom Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, PHAT quarterly EBITDA has changed by +$55.49M (+78.59%)
What is Phathom Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of PHAT is -$212.78M
What is the all-time high TTM EBITDA for Phathom Pharmaceuticals, Inc.?
Phathom Pharmaceuticals, Inc. all-time high TTM EBITDA is -$268.00K
What is Phathom Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, PHAT TTM EBITDA has changed by +$74.36M (+25.90%)